How DHA Plans to End Leidos’ Run as the Military's Health Record Integrator

Why It Matters

Shifting from a single‑integrator model to direct vendor contracts should boost cost transparency, give the government tighter performance control, and reshape the defense health‑IT market.

Key Takeaways

• DHA will replace Leidos with five sole‑source tech contracts
• Oracle, Philips, Amwell, Henry Schein, Solventum named as providers
• Transition starts July 2024, full shift by July 2027
• New model aims for cost transparency and direct government control
• Contracts limited to five years, firm‑fixed price, outcome‑based

Pulse Analysis

The Department of Defense’s health enterprise, known as MHS Genesis, was built around a single‑award contract to Leidos in 2015. That approach accelerated deployment of Cerner’s electronic health record and Henry Schein’s dental system, but as the platform entered its sustainment phase, DHA identified systemic flaws: opaque pricing, duplicated management layers, and limited oversight of the integrator’s performance. These pain points prompted a strategic reassessment of how the government procures and manages critical health‑IT components.

In response, DHA announced a series of five sole‑source agreements with the underlying technology providers—Oracle Health (now owning Cerner), Philips North America, Amwell, Henry Schein, and Solventum Health Information Systems. By contracting directly with the solution owners, DHA aims to eliminate the “pass‑through” costs associated with a middle‑man integrator and to gain clearer insight into licensing fees and service charges. The rollout is phased: Philips and Amwell transition by July 2024, Oracle by November 2024, and the remaining vendors by July 2027. Each contract is structured as a firm‑fixed‑price, outcome‑based deal lasting up to five years, preserving the federal baseline while allowing future open competition for service layers.

The shift has broader implications for the defense health‑IT ecosystem. Leidos, which has built a sizable revenue stream from the integrator role, faces a potential revenue decline, while vendors gain direct access to a $14 billion‑plus defense health market. For the government, the model promises greater fiscal discipline, faster innovation adoption, and stronger leverage in negotiating service‑level agreements. However, success will hinge on DHA’s ability to manage multiple vendor relationships and maintain the unified platform’s interoperability—a challenge that will test the agency’s acquisition expertise in the years ahead.